and duration of stay. The data was recorded and analysed using Microsoft Excel and kept anonymous. After the first review, we applied the teaching sessions for the labour staff/midwives and also introduced the flyer/poster was displayed in theatres, postnatal wards, labour wards. Email sent to all staff at LGH and LRI Maternity units Results. There were 119 admissions between period 1 and 124 admissions between period 2. Temperature recordings within 30 minutes of admission to the Neonatal Unit was measured and documented for babies in first period as 99% and 100% in second period. 100% achievement of admission target temperatures between 36.5 – 37.5°C were recorded as 81% and 86% for respective periods. There were 24 and 21 patients who had temperatures outside the limit. The majority of patients had temperature >36.5 as they have been admitted for sepsis treatment. Babies with hypothermia were >33 and <37 weeks gestational in 42% and 44% in reviews. 50% of babies were above 2.5 kg in period 2. For both periods, babies admitted with a temperature lower than 36.5 were treated for sepsis and they were admitted from labour ward and theatre.

Conclusion An excellent level of documentation compliance was observed.

With minimum intervention, normothermic admissions improved to 5%. There still remains room for improvement in areas to prevent hypothermia. The particular at-risk age group appears to be between 33-37 weeks and weight above 2.5 kg.

CASE REPORT: CONGENITAL CHYLOTHORAX PRESENTING WITH SEVERE HYDROPS IN A LATE PRETERM NEONATE SUCCESSFULLY TREATED WITH OCTREOTIDE

Krešimir Šantić, Darjan Kardum, Mima Sipl, Dalibor Disković, Krešimir Ivaković, Andrijana Šantić. University Hospital Centre Osijek

Fetal hydrops is an accumulation of fluid in more than one extravascular space. Congenital chylothorax is a rare cause of non-immune fetal hydrops, and the prognosis is generally very poor. There is no consensus on the optional treatment of congenital chylothorax. Conservative treatments (low-fat high-protein diets with medium-chain triglycerides, total parenteral nutrition) and surgical interventions are performed. There is mounting evidence for the use of octreotide (a somatostatin analog) in cases nonresponsive to conservative treatment, but no specific recommendation as to the dose and the length of therapy exist so far.

We report a male, late preterm newborn, with a birth weight of 1540g (<2nd centile). After birth baby was constantly jittery, irritable and tachycardic. In initial TRAb was raised at 27.5 and TSH was <0.02. After liaising with a tertiary unit paediatric endocrine team, the baby was started on propranolol and then carbimazole. Symptoms of thyrotoxicosis improved after starting treatment and after 2 weeks baby was discharged from our neonatal unit. Thyroid function as well as TRAb were monitored closely and carbimazole were discontinued by 1 month. Baby has since needed thyroxine replacement therapy, and continues to be closely monitored and managed by the local paediatric team in close consultation with the tertiary paediatric endocrine unit.

Conclusion This is a rare case of fetal and neonatal thyrotoxicosis. It demonstrates that despite maternal treatment with thyroidecetomy and the mother being euthyroid during pregnancy, transplacental passage of TRAb can cause thyrotoxicosis in the foetus and later on the neonate. Although such cases are rare they have a relatively high mortality and morbidity. It shows the significant implications on the baby’s growth and cardiovascular compromise that may occur with thyrotoxicosis in the newborn. In addition it highlights the complex management of this group.

INCIDENCE OF NEONATAL SEPSIS TREATED IN PICU, UNIVERSITY HOSPITAL OF SPLIT, CROATIA

Branka Polić*, Ivana Ćović, Joško Matić, Tanja Kovačević, Tatjana Čatićović Andalč, Julije Meštrović. Department of Paediatrics, University Hospital of Split, Split, Croatia

116 A GRAVE AFFAIR-AN UNUSUAL CASE OF CONGENITAL THYROTOXICOSIS IN A PRETERM BABY CAUSED BY TRANSPLENTAL PASSAGE OF MATERNAL THYROID STIMULATING HORMONE ANTIBODIES DURING PREGNANCY

S Parker*, S Rao, RMJ Anderson, WL Lee. Colchester Hospital Hospital

Intoduction Congenital hyperthyroidism is a rare disease that can affect infants born to mothers with Graves disease. Thyroid stimulating hormone receptor antibodies (TRAb) cross the placenta and can cause foetal and neonatal thyrotoxicosis.

This can have implications on foetal growth and may cause intra uterine growth restriction as well as cardiovascular complications such as foetal tachycardia. Postnatally signs of hyperthyroidism may include tachycardia, hypertension, irritability and poor weight gain. This case illustrates how high maternal TRAb led to foetal thyroid stimulation and thus foetal and neonatal thyrotoxicosis. It also demonstrates the difficulties encountered in managing the affected baby after birth.

Report Baby was born at 34+3 weeks. Maternal history of Graves disease for which mother underwent a thyroidectomy 5 years previously. She was on thyroxone replacement. Mother was euthyroid during pregnancy. Foetal tachycardia was noted from 20 weeks gestation and the thyroid gland showed increased vascularity on antenatal scans. Baby also had a VSD and mild ventriculomegaly.

During this time maternal TRAb was measured at >30 (upper normal range >0.4). Carbimazole was started at 26 weeks, resulting in improvement of foetal tachycardia.

Baby was born in good condition weighing 1540g (<2nd centile). After birth baby was constantly jittery, irritable and tachycardia. Ininitial TRAb was raised at 27.5 and TSH was <0.02. After liaising with a tertiary unit paediatric endocrine team, the baby was started on propranolol and then carbimazole. Symptoms of thyrotoxicosis improved after starting treatment and after 2 weeks baby was discharged from our neonatal unit. Thyroid function as well as TRAb were monitored closely and propranolol and then carbimazole were discontinued by 1 month. Baby has since needed thyroxine replacement therapy, and continues to be closely monitored and managed by the local paediatric team in close consultation with the tertiary paediatric endocrine unit.